[HTML][HTML] Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia—from molecular mechanisms to clinical relevance
Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …
[HTML][HTML] Menstrual blood-derived stem cells: toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases
L Chen, J Qu, T Cheng, X Chen, C Xiang - Stem cell research & therapy, 2019 - Springer
Menstrual blood-derived stem cells (MenSCs) have great potential in the treatment of
various diseases. As a novel type of mesenchymal stem cells (MSCs), MenSCs have …
various diseases. As a novel type of mesenchymal stem cells (MSCs), MenSCs have …
[HTML][HTML] Chronic myeloid leukemia stem cells: targeting therapeutic implications
Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm driven by BCR-
ABL1 oncoprotein, which plays a pivotal role in CML pathology, diagnosis, and treatment as …
ABL1 oncoprotein, which plays a pivotal role in CML pathology, diagnosis, and treatment as …
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours
Molecular heterogeneity characterizes tumours' evolution and adaptation and, because of its
dynamics and continuous changes under external pressure, it is one of the major causes of …
dynamics and continuous changes under external pressure, it is one of the major causes of …
Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities
S Flis, T Chojnacki - Drug design, development and therapy, 2019 - Taylor & Francis
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder of hematopoietic
stem cells. At the molecular level, the disorder results from t (9; 22)(q34; q11) reciprocal …
stem cells. At the molecular level, the disorder results from t (9; 22)(q34; q11) reciprocal …
[HTML][HTML] Mechanisms of resistance and implications for treatment strategies in chronic myeloid leukaemia
Simple Summary Chronic myeloid leukaemia (CML) is a type of blood cancer that is
currently well-managed with drugs that target cancer-causing proteins. However, a …
currently well-managed with drugs that target cancer-causing proteins. However, a …
[HTML][HTML] Unmasking the deceptive nature of cancer stem cells: The role of cd133 in revealing their secrets
J Pospieszna, H Dams-Kozlowska, W Udomsak… - International Journal of …, 2023 - mdpi.com
Cancer remains a leading cause of death globally, and its complexity poses a significant
challenge to effective treatment. Cancer stem cells and their markers have become key …
challenge to effective treatment. Cancer stem cells and their markers have become key …
BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia
B Peter, G Eisenwort, I Sadovnik… - American Journal of …, 2022 - Wiley Online Library
In most patients with chronic myeloid leukemia (CML) clonal cells can be kept under control
by BCR:: ABL1 tyrosine kinase inhibitors (TKI). However, overt resistance or intolerance …
by BCR:: ABL1 tyrosine kinase inhibitors (TKI). However, overt resistance or intolerance …
[HTML][HTML] A role for the bone marrow microenvironment in drug resistance of acute myeloid leukemia
Acute myeloid leukemia (AML) is a heterogeneous disease with a poor prognosis and
remarkable resistance to chemotherapeutic agents. Understanding resistance mechanisms …
remarkable resistance to chemotherapeutic agents. Understanding resistance mechanisms …
[HTML][HTML] Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy
E Andretta, C Costa, C Longobardi, S Damiano… - Frontiers in …, 2021 - frontiersin.org
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of patients with chronic
myeloid leukemia (CML). However, continued use of these inhibitors has contributed to the …
myeloid leukemia (CML). However, continued use of these inhibitors has contributed to the …